1
|
Nagao S, Furihata M, Fukagawa K, Furihata T, Matsuhashi Y, Wada T. Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect Chemother 2017; 23:493-497. [PMID: 28285948 DOI: 10.1016/j.jiac.2017.02.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 01/05/2017] [Accepted: 02/13/2017] [Indexed: 10/20/2022]
Abstract
Oxaliplatin is a platinum-based chemotherapeutic agent that holds a prominent position in the treatment of colorectal and gastric cancers. However, severe oxaliplatin-related vascular pain can be problematic for patients. Here we describe seven patients who experienced severe vascular pain caused by oxaliplatin administration. All seven patients were treated with capecitabine and oxaliplatin or capecitabine plus oxaliplatin with bevacizumab as an adjuvant or a treatment for recurrent colorectal cancer, respectively. Patients experienced intolerable vascular pain during oxaliplatin administration, which continued for several days. Moreover, vascular pain also induced insomnia and appetite loss in all patients. We recommended implantation of a central venous (CV) port to the patients; however, all patients declined this treatment. In addition, various known countermeasures were taken, but were ineffective. Therefore, patients were orally administered oxycodone hydrochloride hydrate (Oxinorm®) 45 min prior to oxaliplatin administration. This pretreatment successfully reduced vascular pain and improved subsequent chemotherapy. Oxinorm® is a fast-acting opioid that can be an effective and practical option for severe vascular pain induced by oxaliplatin. The present report is the first description that emphasizes the usefulness of Oxinorm® to overcome the vascular pain induced by administration of oxaliplatin via a peripheral vein.
Collapse
Affiliation(s)
- Sayaka Nagao
- Department of Gastroenterology, The Mutual Aid Association for Teachers and Officials Sanraku Hospital, 2-5 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8326, Japan
| | - Makoto Furihata
- Department of Chemotherapy, The Mutual Aid Association for Teachers and Officials Sanraku Hospital, 2-5 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8326, Japan.
| | - Kazushi Fukagawa
- Department of Gastroenterology, The Mutual Aid Association for Teachers and Officials Sanraku Hospital, 2-5 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8326, Japan
| | - Tadashi Furihata
- Department of General Surgery, Kyouwa Chuo Hospital, 1676-1 Kadoi, Chikusei-shi, Ibaraki, 309-1195, Japan
| | - Yuki Matsuhashi
- Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifucyou, Hirosaki-shi, Aomori-ken, 036-8562, Japan
| | - Tomonori Wada
- Department of Gastroenterology, The Mutual Aid Association for Teachers and Officials Sanraku Hospital, 2-5 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8326, Japan
| |
Collapse
|